Results from a first-in-human study suggest this new-look device could provide cardiologists and their care teams with another way to treat tricuspid regurgitation in high-risk patients.

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

The 80-year-old patient was experiencing severe TR and already had a HeartMate II LVAD. 

The new valve was placed inside the damaged valve via a catheter that is inserted through a small incision in the patient's neck. 

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates. 

Anita W. Asgar, MD, director, transcatheter valve therapy research at Montréal Heart Institute, discusses advances and new technology for mitral and tricuspid valves at the 2022 Transcatheter Valve Therapies (TVT) meeting.